Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Passiglia Francesco, Reale Maria Lucia, Pasello Giulia, Viscardi Giuseppe, Attili Ilaria, Mazzoni Francesca, Galetta Domenico, Catania Chiara, Andrikou Kallopi, Russo Alessandro, Vavala Tiziana, Bulotta Alessandra, Calvetti Lorenzo, Carta Anna Maria, Grisanti Salvatore, Mariotti Sabrina, La Cava Giulia, Dodi Alessandra, Scotti Vieri, Del Giudice Teresa, Minuti Gabriele, Pizzutillo Elio Gregory, Chiari Rita, Della Corte Carminia Maria, Genova Carlo, Lo Russo Giuseppe, Pignataro Daniele, Pozzessere Daniele, Roca Elisa, Toschi Luca, Bennati Chiara, Borra Gloria, Bettini Anna, Favaretto Adolfo, Gelibter Alain, Gori Stefania, Tabbò Fabrizio, Pagano Maria, Pavan Alberto, Belluomini Lorenzo, Tondulli Luca, Sergi Concetta, Stanzione Brigida, Malapelle Umberto, Novello Silvia, Bria Emilio
Аннотация
METHODS: Patients with surgically resected NSCLC harboring EGFR/ALK wild type disease and PD-L1 TPS ≥ 50%, who received at least one cycle of adjuvant atezolizumab were included. Clinical-pathological and molecular data, safety and efficacy outcomes were collected from the Italian ATLAS real-world registry.
RESULTS: A total of 132 patients were included across 45 Italian centers between July 2022 and August 2024. Lobectomy was performed in 81.1% of cases, with 8.3% pathological stage IIA, 40.2% stage IIB, 43.9% stage IIIA, and 7.6% stage IIIB, according to the eighth TNM staging edition. The median number of atezolizumab cycles was 12.5 (range: 1-20). Treatment related adverse events (TRAEs) during atezolizumab were reported in 44 patients (33.3%), including 11 (8.3%) who experienced multiple TRAEs. Grade ≥ 3 TRAEs were reported in 21 cases (15.9%), leading to treatment discontinuation in 18 (13.6%). The median time to the first onset of TRAEs was 89 days (range: 3-390 days). 15 patients experienced a disease recurrence, including 6 locoregional-only and 9 distant relapses, with a median time since surgery of 13.3 months.
CONCLUSION: This study showed that the safety profile of adjuvant atezolizumab outside of a clinical trial context was comparable to the IMPower-010 study, highlighting the value of the Italian ATLAS registry as source of real-word evidence to optimize the clinical management of NSCLC patients.